Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Achilles Therapeutics

31.03.2021

Achilles Therapeutics Announces Pricing of Initial Public Offering

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of $175.5 million.
Achilles Therapeutics

08.01.2021

Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager

Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Arjan Roozen as VP, Site Head and General Manager, with responsibility for scaling up Achilles’ manufacturing operations to supply cell therapy products for late-stage clinical studies and commercial supply.
Achilles Therapeutics

07.01.2021

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference
Achilles Therapeutics

09.12.2020

Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours today announced the appointment of Lee M. Stern as VP, IR & External Communications where he will lead investor and financial communications activities.
Achilles Therapeutics

01.12.2020

Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Robert Coutts as Chief Financial Officer. Robert has served as Finance Director at Achilles since the Company’s formation in 2017.
Achilles Therapeutics

19.11.2020

Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubscribed Series C financing. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors join existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors and Redmile Group.
Achilles Therapeutics

11.11.2020

Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer

Achilles Therapeutics Limited (“Achilles”), a clinical-stage biopharmaceutical company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the decision by the European Patent Office (“EPO”) to grant European patent EP3288581B, which covers the treatment of cancer using T cells that have been selectively expanded to target clonal neoantigens.
Achilles Therapeutics

07.10.2020

Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Professor Karl Peggs as Chief Medical Officer (CMO) with effect from 4th January 2021. Professor Peggs is an internationally recognised leader in the field of cancer immunology and a founder of the Company.
Achilles Therapeutics

07.07.2020

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.
Achilles Therapeutics

23.06.2020

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.

Load More